logo

Portola Pharmaceuticals Inc. (PTLA)



Trade PTLA now with
  Date
  Headline
12/14/2018 7:18:22 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
12/12/2018 7:54:01 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
12/11/2018 7:03:46 AM CHMP Extends Review Period For Portola Pharmaceuticals’ Ondexxya To February 28, 2019
12/3/2018 9:32:06 PM Portola Updates Interim Results From Ongoing Phase 2a Study Of Cerdulatinib
9/20/2018 8:32:59 AM Portola Pharma Names Scott Garland President And CEO
9/7/2018 8:34:26 AM Portola Pharma Chief Commercial Officer Tao Fu To Resign, Effective Sept. 21
8/31/2018 8:32:44 AM Portola Submits Prior Approval Supplement To FDA For Large-Scale Generation 2 Andexxa Process
8/27/2018 7:00:44 AM William Blair Reiterates Portola Pharmaceuticals Inc. (PTLA) At Outperform
8/9/2018 8:05:16 AM Portola Q2 Net Loss $106.2 Mln Or $1.61/Shr Vs Loss $69.7 Mln Or $1.22/Shr Last Year
7/27/2018 8:24:41 AM European CHMP Maintains Negative Opinion On Portola Pharma’ Betrixaban Following Appeal
7/3/2018 8:35:29 AM Portola Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/25/2018 8:33:39 AM Portola Pharma Appoints Veteran Glenn Brame As SVP Of Technical Operations
6/19/2018 4:51:19 AM New Drugs Approved In May
6/4/2018 8:38:26 AM Portola Pharma : Interim Phase 2a Study Results Show Broad Clinical Activity Of Oral SYK/JAK Inhibitor Cerdulatinib